NEW YORK, July 12, 2017 /PRNewswire/ --
If you want a Stock Review on A, ALR, Q or TMO then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. Featured on DailyStockTracker.com this morning are research reports on: Agilent Technologies Inc. (NYSE: A), Alere Inc. (NYSE: ALR), Quintiles IMS Holdings Inc. (NYSE: Q), and Thermo Fisher Scientific
On Tuesday, shares in California headquartered Agilent Technologies Inc. recorded a trading volume of 2.98 million shares, which was above their three months average volume of 2.01 million shares. The stock ended the session 0.10% lower at $59.80. The Company's shares have gained 1.00% in the last one month, 13.43% over the previous three months, and 31.26% on an YTD basis. The stock is trading 2.20% above its 50-day moving average and 17.24% above its 200-day moving average. Moreover, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have a Relative Strength Index (RSI) of 55.38.
On July 10th, 2017, Agilent Technologies has named Dr. Gary J. Patti as the recipient of the prestigious 2017 Agilent Early Career Professor Award. Dr. Patti, Associate Professor, Department of Chemistry in Arts and Sciences, Washington University in St. Louis, was selected for his contributions to the detection of metabolomics changes in whole organisms and their utility for drug discovery, early detection, characterization, and surveillance of cancer as well as other diseases and conditions. The free research report on A is available at:
Massachusetts headquartered Alere Inc.'s stock closed the day 0.04% higher at $50.35 with a total trading volume of 872,276 shares. The Company's shares have advanced 0.78% in the past month, 18.58% in the previous three months, and 29.20% since the start of this year. The stock is trading 2.07% and 17.75% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Alere, which provides diagnostic tests for infectious disease, cardiometabolic disease, and toxicology, have an RSI of 58.16.
On July 07th, 2017, Alere announced that its shareholders have voted to approve the previously announced amended merger with Abbott. In a final count of the voting results, approximately 63 million of votes cast at a special meeting voted in favor of the amended merger, representing over 72.5% of all outstanding Alere's shares as of the May 31st, 2017 record date. The complimentary report on ALR can be downloaded at:
Shares in North Carolina headquartered Quintiles IMS Holdings Inc. recorded a trading volume of 606,687 shares. The stock ended yesterday's trading session 0.17% lower at $88.12. The Company's shares have advanced 2.29% in the past month, 11.76% in the previous three months, and 15.87% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 2.16% and 10.24%, respectively. Furthermore, shares of Quintiles IMS, which provides integrated information and technology-enabled healthcare services, have an RSI of 50.79.
On June 26th, 2017, Quintiles IMS announced the general availability of a new category of pharmaceuticals commercial operations SaaS software called Orchestrated Customer Engagement (OCE) in the winter of 2017. This new category of enterprise SaaS software empowers pharmaceutical commercial teams to better coordinate and streamline several commercial functions. Those functions include multi-channel marketing, customer relationship management, medical affairs, market access and home office operations, which can now work together to deliver an orchestrated customer engagement experience. Visit us today and download our complete research report on Q for free at:
Thermo Fisher Scientific
Massachusetts headquartered Thermo Fisher Scientific Inc.'s stock finished Tuesday's session 0.55% higher at $178.64. A total trading volume of 2.13 million shares was traded, which was above their three months average volume of 1.43 million shares. The Company's shares have advanced 2.12% in the last one month, 16.42% over the previous three months, and 26.61% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.11% and 14.03%, respectively. Additionally, shares of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under several brands worldwide, have an RSI of 65.63.
On July 03rd, 2017, Thermo Fisher Scientific announced that it will release its financial results for Q2 before the market opens on July 26th, 2017. The Company will also hold a conference call on that same day at 8:30 a.m. EDT to discuss its Q2 financial performance as well as future expectations. Get free access to your technical report on TMO at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...
Blount's disease is a developmental disorder in which the shinbone is affected, resulting in ...View All